1.Date of occurrence of the event: 2022/02/08
2.Company name: OBI Pharma Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): Head office
4.Reciprocal shareholding ratios: Not applicable
5.Cause of occurrence: Please refer to the press release on our website for preclinical animal study results of OBI’s COVID-19 vaccine. https://www.obipharma.com/
6.Countermeasures: None
7.Any other matters that need to be specified: New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.